AIM ImmunoTech Inc is trading 85% down today at $0.41 as investors react to significant shareholder dilution following recent equity and warrant issuances.
- The company regained compliance with NYSE American listing standards after resolving a stockholder equity deficiency through capital raises totaling approximately $5.2 million.
- Equity and warrant issuances conducted between May 21 and June 10 boosted stockholders’ equity but resulted in substantial dilution for existing shareholders.
- The sharp selloff follows the company's efforts to stabilize its listing status at the cost of its share structure.